Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 222,439 |
|
|||||
| News | - | ||||||
| Day High | 6.50 | Low High |
|||||
| Day Low | 6.32 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Larimar Therapeutics Inc | LRMR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.46 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.48 | 6.32 | 6.50 | 6.46 | 6.46 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,477 | 222,439 | $ 6.41 | $ 1,426,443 | - | 2.18 - 13.68 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:02:04 | priorref | 291 | $ 6.46 | USD |
Larimar Therapeutics (LRMR) Options Flow Summary
Larimar Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 63.16M | 63.80M | - | 0 | -36.95M | -0.58 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Larimar Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LRMR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.24 | 7.29 | 6.18 | 6.54 | 356,715 | -0.78 | -10.77% |
| 1 Month | 7.32 | 8.065 | 6.18 | 7.14 | 385,723 | -0.86 | -11.75% |
| 3 Months | 5.94 | 13.68 | 5.6408 | 9.67 | 680,233 | 0.52 | 8.75% |
| 6 Months | 2.81 | 13.68 | 2.18 | 8.65 | 386,586 | 3.65 | 129.89% |
| 1 Year | 4.47 | 13.68 | 2.18 | 6.73 | 314,110 | 1.99 | 44.52% |
| 3 Years | 14.26 | 15.49 | 1.53 | 6.19 | 208,483 | -7.80 | -54.70% |
| 5 Years | 12.00 | 25.87 | 1.53 | 6.92 | 171,333 | -5.54 | -46.17% |
Larimar Therapeutics Description
| Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
